Join the Global Conversation on Health Equity in Bleeding Disorders – WFH
World Federation of Hemophilia – WFH shared a post on LinkedIn:
“Health equity for people with bleeding disorders must be part of the global health agenda.
During the 79th World Health Assembly in Geneva, the World Federation of Hemophilia (WFH), will co-host a Side Event on ‘Advancing Health Equity for Bleeding Disorders’ together with the Ministry of Health of the Republic of Armenia, Rare Diseases International, and the Swiss Haemophilia Society, co-sponsored by the Ministry of Health and Population of Egypt.
The Side Event brings together global health leaders, policymakers, healthcare providers, and patient advocates.
It will explore barriers and strategies to improve equitable access to diagnosis, treatment, and care worldwide.
Held ahead of the anticipated adoption of the Member State-led WHA resolution on hemophilia and other bleeding disorders, this Side Event reflects growing global momentum toward health equity for the bleeding disorders community.
Geneva, Switzerland
May 17, 2026
Follow the livestream online.”
Other posts about World Federation of Hemophilia on Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight